SEC Filing Summary: ADVENTRX Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
ADVENTRX Pharmaceuticals, Inc. filed this Current Report on Form 8-K on March 10, 2011. The filing serves to announce the Company's financial results for the three months and the full year ended December 31, 2010. The report references a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1). The filing notes that the press release includes non-GAAP "pro forma" cash information intended to reflect the Company's cash position following a January 2011 equity financing.
Material Changes and Unusual Items
- Equity Financing: The Company completed an equity financing in January 2011, which is the basis for the pro forma cash information presented in the associated press release.
- Non-GAAP Measures: The filing explicitly states that pro forma cash information is not defined by GAAP and should be viewed as supplementary to GAAP measures. Reconciliations are provided in the press release.
Guidance, Outlook, and Management Commentary
Management utilizes the pro forma cash information to assess the Company's cash position entering 2011 and to budget for 2011 operations. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard disclosure regarding the non-GAAP nature of the pro forma data.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP revenue, net loss, and cash balance figures for the periods ended December 31, 2010.
- Examine the reconciliation between GAAP and non-GAAP pro forma cash information to understand the impact of the January 2011 equity financing.
- Verify the details of the January 2011 equity financing to confirm the capital raised and its effect on liquidity.
- Confirm that the pro forma data is not being used as a substitute for GAAP financial statements in investment analysis.